May 28 (Reuters) - ARCA Biopharma Inc:
* ARCA BIOPHARMA ANNOUNCES AB201 DEVELOPMENT PROGRAM FOR TREATMENT OF COVID-19 ASSOCIATED COAGULOPATHY
* ARCA BIOPHARMA - ANTICIPATES FILING AN IND IN Q3 2020 & INITIATING LATE-STAGE CLINICAL TESTING IN H2 OF THIS YEAR Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.